Sugi Predict

Sugi Predict / Compounds / SCHEMBL4908399

SCHEMBL4908399

SCHEMBL4908399

CSc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 19/20 0.72
▸ CSNK1D P48730 4/20 0.71
▸ MAPK13 O15264 3/20 0.71
▸ MAPK12 P53778 3/20 0.71
▸ MAPK11 Q15759 3/20 0.71
▸ PRKD3 O94806 3/20 0.71
▸ MAP4K4 O95819 3/20 0.71
▸ CSNK1A1 P48729 3/20 0.71
▸ MINK1 Q8N4C8 3/20 0.71
▸ MAP4K5 Q9Y4K4 3/20 0.71
▸ EGFR P00533 2/20 0.71
▸ LCK P06239 2/20 0.71
▸ MAPK9 P45984 2/20 0.71
▸ PRKD2 Q9BZL6 2/20 0.71
▸ PRKCA P17252 2/20 0.71
▸ KDM4E B2RXH2 1/20 0.71
▸ RAF1 P04049 1/20 0.71
▸ CYP1A2 P05177 1/20 0.71
▸ CYP2D6 P10635 1/20 0.71
▸ CYP2C9 P11712 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4908397 1.00 MAPK14 (0.72) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL20550929 0.91 MAPK14 (0.72) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL31447748 0.91 MAPK14 (0.72) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL6578849 0.89 MAPK14 (0.68) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL4585943 0.89 MAPK14 (0.74) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL4915940 0.89 MAPK14 (0.73) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL4915688 0.89 MAPK14 (0.73) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL6578852 0.87 MAPK14 (0.66) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL7772152 0.85 MAPK14 (0.82) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL4912960 0.84 MAPK14 (1.00) MAPK14CSNK1DMAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS PROTTER ANDREW A 2008-05-08 — — US disclosed
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase PROTTER ANDREW A 2008-02-14 — — US disclosed
US-6387898-B1 USING IMIDAZOLE COMPOUND SMITHKLINE BEECHAM CORPORATION 2002-05-14 — — US disclosed
US-6329526-B1 Cycloalkyl substituted imidazoles SMITHKLINE BEECHAM CORPORATION 2001-12-11 — — US disclosed
US-6251914-B1 TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION 2001-06-26 — — US disclosed
EP-1019396-A1 NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES SmithKline Beecham Corporation (US) 2000-07-19 — — EP disclosed
WO-1999001452-A1 NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES SMITHKLINE BEECHAM CORPORATION (US) 1999-01-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS MAPK1, BMP2, MAPK3 MAPK14 23/4885CSNK1D 3484/4885MAPK13 15/4885
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase OPRK1, OPRL1, MAPK3 MAPK14 36/4885CSNK1D 505/4885MAPK13 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.